New chronic kidney disease drug ‘Kerendia’ is expected to receive reimbursement status.

According to the industry, Bayer has reached a settlement with National Health Insurance Service (NHIS) in negotiations for the reimbursement pricing of its drug Kerendia(finerenone), which is used to treat chronic kidney disease in patients with type 2 diabetes, at the end of the year.

When it passes the Heath Insurance Policy Review Committee in January, Kerendia is expected to be listed for reimbursement starting February.

Kerendia received approval in Korea last year. It is indicated to reduce the risk of sustained eGFR (estimated Glomerular Filtration Rate, eGFR) decline